Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/Latest News/Phase III Trials of Bharat Biotech’s Oral Cholera Vaccine: Key Insights
Latest News

Phase III Trials of Bharat Biotech’s Oral Cholera Vaccine: Key Insights

By adminitfy
May 21, 2025 2 Min Read

Vaccine maker Bharat Biotech announced on Wednesday that its oral cholera vaccine, Hillchol, has successfully completed phase III clinical trials. This double-blind, randomized trial evaluated the vaccine’s safety, immunogenicity, non-inferiority, and lot-to-lot consistency. The study involved 1,800 participants ranging from infants to adults across ten clinical sites in India. The primary endpoint was to determine the proportion of participants achieving a greater than four-fold increase in vibriocidal antibody titres against the Ogawa and Inaba serotypes 14 days after receiving two doses. Secondary endpoints included Geometric Mean Titre (GMT) measurements and safety assessments.

According to Bharat Biotech, Hillchol showed a greater than four-fold increase in vibriocidal antibodies against both Ogawa (68.3%) and Inaba (69.5%) serotypes, demonstrating non-inferiority to licensed vaccines. This result supports Hillchol’s potential as an effective oral cholera vaccine, as detailed in the study published in the Vaccine journal on ScienceDirect. Adverse events associated with the vaccine were mild and comparable to those of the comparator vaccine, Shanchol. The vaccine was well-tolerated and immunogenic across all age groups, including infants, children, and adults, indicating readiness for distribution within the coming months.

Krishna Ella, Executive Chairman of Bharat Biotech, emphasized the company’s commitment to advancing vaccines through rigorous research and comprehensive clinical trials. He noted that this publication reflects their dedication to providing affordable, effective, and accessible vaccines to populations in need. Cholera, a vaccine-preventable disease, has experienced a surge in outbreaks alongside a global vaccine shortage. Hillchol utilizes a simplified single stable O1 Hikojima strain, aiming to enhance production efficiency and affordability, especially in lower- and middle-income countries where waterborne diseases remain a serious health threat.

The global demand for oral cholera vaccines (OCVs) approaches 100 million doses annually, but with only one manufacturer currently supplying the market, there is a significant shortage. Bharat Biotech’s facilities in Hyderabad and Bhubaneswar can produce up to 200 million doses of Hillchol. The vaccine, known by its trade name BBV131, has already received market authorization in India.

Original Source: https://www.thehindu.com/news/cities/Hyderabad/phase-iii-clinical-trials-of-bharat-biotechs-oral-cholera-vaccine-over/article69602317.ece
Category:
Tags:
Publish Date: 2025-05-21 20:25:00

Author

adminitfy

Follow Me
Other Articles
Previous

AIADMK Urges Urgent Action: Demand for 50% Government Quota Seats in Private Medical Colleges!

Next

Bitcoin Soars to New All-Time High: Breaks January Record with Unstoppable Momentum!

No Comment! Be the first one.

Leave a Reply Cancel reply

You must be logged in to post a comment.

Search...

Recent Posts

  • Guwahati Waterbodies to Be Mapped Under Assam's New Conservation Act
    Guwahati Waterbodies to Be Mapped Under Assam’s New Conservation Act
    by adminitfy
    November 21, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • Guwahati Waterbodies to Be Mapped Under Assam’s New Conservation Act
  • Animesh Debbarma Cabinet Rumours Dismissed: No Reshuffle
  • Video: El Chapo Isidro Meza Flores Caught in Black Hawk Raid
  • Massive Fire Guts 10+ Shops, Houses in Arunachal’s Ruksin Market
  • The Compliance Paradox: Why Enforcement Systems Ignore Their Best Evidence
  • November 2026 (663)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.